6855 Share Price Performance
HK$37.56
-11.59 (-23.58%)
47.7% undervalued intrinsic discount
HK$71.81
Fair Value
Price HK$37.56
AnalystLowTarget HK$71.81
AnalystConsensusTarget HK$101.03
AnalystHighTarget HK$114.00
Fair ValueHK$71.81
Share Pricen/a
Ascentage Pharma Group International Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
6855 Community Narratives
AN
Fair Value
·Fair Value HK$71.81 47.7% undervalued intrinsic discount
Takeda Payments Will Undermine Revenue Amid China NRDL Pressures
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value HK$101.03 62.8% undervalued intrinsic discount
Takeda Deal And Olverembatinib Trials Will Open Global Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value HK$114 67.1% undervalued intrinsic discount
Precision Oncology And Global Aging Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Takeda Payments Will Undermine Revenue Amid China NRDL Pressures
Key Takeaways Over-reliance on non-recurring partnership payments and pipeline-stage products renders future revenue and earnings highly uncertain amidst rising competition and healthcare cost pressures. Intensifying regulatory, geopolitical, and funding challenges threaten global expansion, product launches, and long-term financial sustainability, exposing the company to dilution and operational cutbacks.Read more
AN
HK$71.81
47.7% undervalued intrinsic discount
Fair Value
Profit Margin
15.91%
Future PE
155.93x
Price in 2029
HK$88.89
Precision Oncology And Global Aging Will Open New Markets
Key Takeaways Strategic collaborations, expanding reimbursement, and efficient commercialization are set to drive recurring revenues, boost margins, and accelerate global growth. A strong, innovative pipeline and promising drug combinations position the company for durable pricing power and high-margin opportunities in precision oncology.Read more
AN
HK$114
67.1% undervalued intrinsic discount
Fair Value
Profit Margin
66.89%
Future PE
11.69x
Price in 2029
HK$141.53
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.Read more
AN
HK$101.03
62.8% undervalued intrinsic discount
Fair Value
Profit Margin
20.61%
Future PE
107.68x
Price in 2029
HK$124.82
Trending Discussion
Recently Updated Narratives
AN
6855: Late Stage Oncology Readouts Will Drive Future Upside Potential
Fair Value: HK$71.81 47.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
6855: Late Stage Hematology Readouts Will Drive A More Constructive Outlook
Fair Value: HK$114 67.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
6855: Late Stage Oncology Pipeline Will Drive Bullish Repricing Potential
Fair Value: HK$101.03 62.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ascentage Pharma Group International Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.38
- 91.48%
- -216.47%
- 146.7%
About 6855
- Founded
- 2009
- Employees
- 767
- CEO
- WebsiteView website
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
